Ally Perlina is a visionary innovator who translates complex data into scalable products.
As Chief Science Officer for CureMatch, Inc., a San Diego company delivering groundbreaking artificial intelligence (AI) technology for clinical decision support, Ally Perlina leads the clinical, biological, data science and product development teams.
With her leadership, CureMatch empowers oncologists to address the immense complexity behind cancer genomics so that they can select therapies that are uniquely matched to the molecular profile of the individual patient’s tumor – supporting better outcomes.
Ally’s experience also includes leadership roles with Viome and Human Longevity; SBP Medical Discovery Institute, Quest Diagnostics; and Thomson Reuters where she worked with pharmaceutical companies. She researched clinical genomics of brain tumors at UCLA’s Ph.D. program in Human Genetics, where she also earned her M.S. degree. She received her B.S. in Biochemistry and Cell Biology from UCSD. She is a published author and inventor on several patents.
Medical Director, Immunohistochemistry and Molecular Pathology; Physician Lead, Research, William Osler Health System
Dr. Brandon Sheffield is an anatomic and molecular pathologist with the William Osler Health System. He is currently serving as the Medical Director of Immunohistochemistry and Molecular Pathology, and the Physician Lead of research for William Osler Health System.
Dr. Sheffield’s principal focus is on the delivery of personalized medicine and precision oncology, with a specific attention to making molecular testing available to community cancer patients in Canada.